Mr. David Preiner reports

MEDIVOLVE ANNOUNCES LAUNCH OF INVESTOR AWARENESS CAMPAIGN AND REFILING OF Q2 2022 FINANCIAL STATEMENTS

Medivolve Inc. has launched an investor marketing campaign to raise awareness of the company in the investing community. The company also has amended and refiled its condensed interim consolidated financial statements and corresponding management's discussion and analysis for the six-month period ended June 30, 2022.

Wallstreet Investor Club

Medivolve has entered into a service agreement with Lion Capital Investment Ltd., pursuant to which Lion will provide marketing services under the trade name Wallstreet Investor Club for a period of six months for a fee of $250,000 (U.S.). Lion is a marketing consultant based in the Cayman Islands. Lion has an exclusive partnership with Zemanta for content distribution and ad platforms, which gives Lion access to a multitude of other sites. Neither Lion, nor any of its principals currently owns any securities, directly or indirectly, of the company or has any intention to acquire any such securities.

Refiled second quarter 2022 financials and Q2 2022 MD&A

The company has revised and refiled its Q2 2022 financials and Q2 2022 MD&A. The unaudited condensed interim consolidated financial statements for the three and six months ended June 30, 2022, and 2021, filed on SEDAR on Aug. 15, 2022, have been revised to correct: the date of the statements of cash flows, which erroneously referred to the current and comparative periods disclosed as Dec. 31, 2022, and 2021, instead of June 30, 2022, and 2021; and the financial information presented in the statements of cash flows for the comparative period ended June 30, 2021, all of which was incorrect, except for net (loss) for the period. The Q2 2022 MD&A has been revised to correct commentary related to the statements of cash flows, reflecting changes to the financial information for the 2021 comparative period presented in the revised Q2 2022 financials, and an erroneous reference to the three months ended March 31, 2022, which should refer to the six months ended June 30, 2022. The corrective disclosure was made at the request of the Ontario Securities Commission in connection with a continuous disclosure review.

About Medivolve Inc.

Medivolve is a health care technology company that seeks to reinvent the U.S. health care system by leveraging a bespoke telehealth platform, a clinical diagnostic network and a data-driven artificial intelligence framework to improve patient care.

The company was born out of the health care crisis: to rethink, relearn and, ultimately, reimagine a better way for the health care system to operate. Its network of retail collection sites plays an important role in recovery by giving Americans access to fast, accurate and inexpensive clinical services when and where they need it. These centres will also play a pivotal role in diagnostic testing, vaccinations and other point-of-care services. It is building disruptive technologies to make it easier and faster to identify, treat and prevent medical issues. In doing so, it is working to give patients a holistic and empowered view of their personal health.

Its long-term mission is to address systemic issues in the nation's fragmented, overly complex and expensive health care system. Medivolve's next phase of growth is about pivoting the model and putting the pieces together to build a profitable healthtech company. It is developing a singular, streamlined technology network to provide data-driven physician consultations, clinical diagnostics and prescription services. Its team is united by a powerful, singular purpose: harnessing the transformative power of technology to create healthier lives.

Underpinned by a bespoke, artificial-intelligence-driven platform, it is developing a system that constantly gets smarter, takes the guesswork out of diagnostics and flags critical health issues to help physicians, delivering a high level of personalization for each patient.

We seek Safe Harbor.